Sign inJoin waitlistJoin the waitlist

Mark Tyson

Program Director · Mayo Clinic College of Medicine and Science

Credentials: · · · · ·

History

Mayo Clinic College of Medicine and Science
Present
Vanderbilt University Medical Center
Present
Vanderbilt University Medical Center
Present

Vanderbilt University Medical Center
2019–2020
Vanderbilt University School of Medicine
2018–2019
Pediatric Urology
Vanderbilt University Medical Center
2016–2018
Urology
Mayo Clinic College of Medicine and Science
2012–2016
Preliminary General Surgery
Mayo Clinic College of Medicine and Science
2011–2012
Geisel School of Medicine at Dartmouth
2006–2010

Research

Association Between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes After 3 Years
JAMA · 2017 · 285 citations
Enhanced Recovery Pathways Versus Standard Care After Cystectomy: A Meta-analysis of the Effect on Perioperative Outcomes
Systematic review or meta-analysis · European Urology · 2016 · First of 2 authors · Corresponding · 166 citations
Childbearing and pregnancy characteristics of female orthopaedic surgeons
The Journal of bone and joint surgery. American volume · 2012 · 139 citations

Mitchell Humphreys
30 papers
EC
Erik Castle
26 papers
Kassem Faraj
20 papers · 20 as a resident
AD
Adri Durant
18 papers · 18 as a resident
Paul Andrews
16 papers
Haidar Abdul-Muhsin
12 papers · 10 as a resident
Daniel Barocas
10 papers
David Penson
10 papers
Sam Chang
10 papers
Matthew Resnick
9 papers
Stephen Boorjian
9 papers
Timothy Lyon
9 papers · 9 as a resident

Clinical trials

Urine-based Molecular Testing vs Cystoscopy for Surveillance of Nonmuscle Invasive Bladder Cancer (NMIBC)
Principal investigator · Completed
Mayo Clinic
2023–2025
Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship Study
Principal investigator · Active not recruiting
Mayo Clinic
2018–2029
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2027
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2025–2028